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Most of the publications on isotretinoin, pregnancy and compliance with the preg-
nancy prevention programme (PPP) originate from North America. Information
specific for the European situation is very limited. The aim of this study was to
identify publications describing the use of isotretinoin in humans and the compli-
ance with the PPP in Europe, a systematic search in Medline and Embase was con-
ducted using the terms ‘isotretinoin, pregnancy (and Europe)’. Furthermore, a
manual search in publications was performed. A total of 17 publications were iden-
tified. Publications consisted of case reports of exposed pregnancies, surveys among
dermatologists or pharmacists and database studies evaluating compliance with the
PPP. The studies and surveys dealt with groups of patients exposed to isotretinoin
before or during pregnancy and ⁄or compliance with the isotretinoin PPP. Where
the information was provided, in 6–26% of cases isotretinoin was prescribed in full
accordance with the PPP. Pregnancy incidence was seen in 0Æ2–1Æ0 per 1000
women of childbearing age using isotretinoin. Between 65% and 87% of these
pregnancies were terminated. This review of studies in Europe performed to date
shows failures in the implementation of the PPP. Therefore, the isotretinoin PPP
must be scrutinized to identify whether new measures should be taken or whether
the failures in the implementation need to be corrected. New measures should take
into account the definition of the ultimate goal of a PPP and the acceptable burden.
In the meantime, stakeholders could make a start with adjustments in the imple-
mentation of the PPP by taking responsibility and enhancing the performance by
explicit instructions, monitoring the performance and adjusting, if necessary.
Isotretinoin was authorized in the U.S.A. in 1982 and in the
EU in 1983 and was marketed by Roche as Roaccutane for
the treatment of severe acne. In 1983 the first reports of con-
genital malformations appeared1 despite warnings about the
teratogenic risks in pregnancy. The retinoic acid embryopathy
described by Lammer et al.2 has a relative risk of 26%. This
embryopathy consists of craniofacial, cardiac, thymic and cen-
tral nervous system malformations. The relative risk of con-
genital malformations due to isotretinoin exposure during
pregnancy is comparable to the relative risk for thalidomide.
In 1988 the marketing authorization holder implemented a
pregnancy prevention programme (PPP) for oral isotretinoin,
which was included in the product information worldwide. In
the U.S.A., studies on the compliance with the PPP were per-
formed by research institutes,3,4 by the Food and Drug
Administration (FDA)5 and by Roche. Because of a lower than
expected compliance a more strict PPP for isotretinoin was
implemented in the U.S.A. in 2002, ‘SMART’, and an even
stricter PPP was implemented in 2006, ‘iPledge’.
In 1997, recommendations for the prescribing and dispens-
ing of isotretinoin were strengthened in France. In 2001 the
first generic formulation of isotretinoin became available. Cur-
rently there are at least 70 generic oral isotretinoin formula-
tions on the market in Europe (communication between EU
member states). Because of differences in the PPPs between
the different isotretinoin-containing products, a harmonization
procedure for all isotretinoin-containing products was
approved by the European Commission in October 2003. Dur-
ing this harmonization procedure not only was the PPP
harmonized but also the indication for use was amended to a
stricter second-line indication for oral isotretinoin. Currently
in Europe, isotretinoin is indicated as a treatment for severe
forms of acne resistant to adequate courses of standard therapy
with systemic antibacterial medication and topical therapy.
 2011 The Authors
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The literature search revealed that most of the publications
on isotretinoin, pregnancy and compliance with the PPP origi-
nate from North America. Information specific for the Euro-
pean situation is very limited. The aim of the current study
was therefore to perform a review of publications on the use
of isotretinoin in pregnancy and compliance with the PPP in
Europe.
Materials and methods
A search was performed in Medline with the Medical Subject
Headings (MeSH) terms ‘isotretinoin, pregnancy, Europe’ and
‘isotretinoin, pregnancy’. Embase was searched with the terms
‘isotretinoin, pregnancy’. The Medline searches identified 10
and 302 publications, respectively, on 31 August 2009. On the
same date, the Embase search identified a total of 641 publica-
tions. A language selection was made for publications in Eng-
lish, French, German or Dutch. Other selection criteria were
studies, case reports, oral isotretinoin, and human data. The
searches were supplemented with manual analyses of references
of the leading publications and all identified European publica-
tions dealing with systemic use of isotretinoin and birth defects.
Identifying studies on compliance with the use of oral iso-
tretinoin, surveys and case reports resulted in 17 European
publications, which are discussed below.
Results
A total of 17 publications were identified,6–22 consisting of
case reports of exposed pregnancies, surveys among dermatolo-
gists or pharmacists and database studies evaluating the compli-
ance with the PPP. The results are presented in Tables 1 and 2.
Table 1 Identified studies and surveys
Author(s) Title Country Year Type Source
Autret et al.6 Isotre´tinoı¨ne (Roaccutane) chez
la femme en aˆge de procre´er:
insuffisance de suivi des
recommandations de prescription
France 1997 Study Questionnaires to pharmacovigilance
organizations and pharmacists
Holmes et al.9 The prescription of isotretinoin to
women: is every precaution taken?
U.K. 1998 Survey Questionnaire survey of dermatologists




Sweden 1999 Study Medical Birth Registry for infants in
Sweden
Autret-Leca et al.7 Roaccutane chez la femme en aˆge
de procre´er: e´tude de l’impact du
renforcement des
recommandations de prescription
France 2000 Study All pregnancies from several sources in
France, such as pharmacovigilance
centres, Roche and TIS and sample
of drug prescriptions
Wildfang et al.11 Isotretinoin in Denmark –
20 years on
Denmark 2002 Survey Questionnaire survey of dermatologists
Dutronc et al.12 Modalite´s de prescription et de
surveillance de l’isotre´tinoı¨ne den
Coˆte d’Or: e´tude prospective chez
67 femmes en aˆge de procre´er
France 2004 Study Questionnaire to randomly selected
pharmacies
Bensouda-Grimaldi et al.8 Isotre´tinoı¨n: suivi de l’application
des recommandations des
prescriptions chez les
femmes en aˆge de procre´er
France 2005 Study All pregnancies from several sources
in France, such as pharmacovigilance
centres, Roche and other MAH and
TIS and sample of drug prescriptions
De Santis et al.13 The need for restricted prescription
of retinoid acid derivative
isotretinoin to prevent
retinoid teratogenicity
Italy 2007 Study TIS database
Jeanmougin et al.14 Aide au bon usage de l’isotre´tinoı¨n
en pratique libe´rale: observatoire
prospectif de 1263 patients
acne´iques
France 2009 Study Prospective observational, national,
multicentre study
Schaefer et al.15 Isotretinoin exposure and
pregnancy outcome: an
observational study of the
Berlin Institute for Clinical
Teratology and Drug Risk
Assessment in Pregnancy
Germany 2010 Study TIS database with prospective and
retrospective cohorts compared with
controls
MAH, marketing authorization holder(s); TIS, Teratology Information services.
 2011 The Authors
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Taking into account the selected publications, France con-
tributed more than half the publications (n = 10) of which
nine were in French; all other publications were in English.
Studies and surveys
The identified studies and surveys among dermatologists or
pharmacists deal with groups of patients exposed to isotretino-
in before or during pregnancy and ⁄or compliance with the
PPPs for isotretinoin. Parts of the results of these studies and
surveys are presented in Tables 3 and 4.
Three of the French studies were performed by the group
of Autret-Leca et al.6–8 within the same database and showed a
development over time.
In France, the incidence of pregnancies with isotretinoin
use remains stable between 0Æ2 and 1Æ0 per 1000 women of
childbearing age. In the last of this group’s publications, by
Bensouda-Grimaldi et al.,8 the covered period was divided
because of the authorization of generic formulations of iso-
tretinoin in 2001.
In the first study,6 a total of 318 pregnancies were reported
over a period of 9 years (1987–1995). During and after
isotretinoin use, in 84% contraception was not prescribed or
was prescribed with poor compliance.
In the second study,7 37 pregnancies were reported over a
22-month period (March 1997 to December 1998). Restricted
measures for pregnancy prevention came into force in March
1997 and this study was to evaluate the new procedures. In
the third study,8 103 pregnancies exposed to isotretinoin
occurred over a 4-year period (1999–2002).
The second part of these three studies concerned prescription
surveys on the recommendations of the PPP current at that time.
Questionnaires were completed by the pharmacist while inter-
viewing female patients with isotretinoin prescriptions.
In the first study,6 230 pharmacies were selected and 102
actually participated in the questionnaire survey. A total of
173 questionnaires were analysed. The prescriptions covered
3 months (range 1–16 months) for isotretinoin and in
13 cases (8%) were accompanied with a prescription for a
contraceptive.
In the second study,7 of the 310 selected pharmacies 105
pharmacies actually participated in the questionnaire survey. A
total of 165 questionnaires were filled out. In 27 cases the
contraceptive method did not fulfil the PPP criteria, for
instance Diane was prescribed in 19 cases and in 17 cases
the contraceptive method was poorly described.
In the third study,8 45 pharmacies participated and 68
questionnaires were analysed. In 47% the prescription con-
cerned Roaccutane and in the other cases generic formula-
tions of isotretinoin.
A questionnaire survey with dermatologists practising in
Scotland9 was performed. Sixty-four of the 90 dermatologists
completed the questionnaire of which there was a similar pro-
portion of men and women, and clinical experience and age.
Patients were asked about the possibility of a pregnancy in
95% of the women older than 16 years and in 70% of the
women younger than 16 years. In patients younger than
16 years, in only 41% was a pregnancy test routinely per-
formed. Verbal and written advice on avoiding pregnancy was
given in 97% of cases. In general, oral contraceptives were
considered an adequate form of contraception, for 75% of the
physicians progestogen-only or an intrauterine device (IUD)
was also suitable and for 15% barrier methods such as con-
doms were also acceptable. In 67% the dermatologists asked
the general practitioner to prescribe an oral contraceptive and
in 27% Diannette was suggested. With 79% of the physicians
isotretinoin was started after at least 1 month of oral contra-
ceptive use. In only 6% of cases was a pregnancy test per-
formed at each visit. Ten per cent of the physicians did not
warn their patients to avoid pregnancy for 1 month after dis-
continuation of isotretinoin; a number of physicians recom-
mended avoidance for 2 months after stopping isotretinoin.
A Swedish study10 was performed on the Medical Birth
Registry for infants born during 1982 through 1989. In Swe-
den isotretinoin may be prescribed only on a named patient
basis. A total of 301 pregnancies were identified in women
who had received isotretinoin. There were 173 infants
(including eight twins) whose mothers had been treated with
isotretinoin before pregnancy, of which two infants had major
birth defects: one child with a ventricular septum defect and
Table 3 Information on pregnancies associated with isotretinoin use
Autret et al.6 Autret-Leca et al.7 Bensouda-Grimaldi et al.8 Schaefer et al.15
Period 1987–1995 March 1997–December 1998 1999–2002 1993–2008
Pregnancy incidence (per 1000)a 0Æ2–0Æ7 0Æ4–0Æ8 0Æ3–1Æ0 ⁄0Æ3–0Æ8b
Terminated pregnancies (%) 81 65 87 76
Pregnancies during treatment with
isotretinoin (%)
16 49 29 47c




aPer 1000 women of childbearing age using isotretinoin. bPeriod was divided because of authorization of generic formulations of isotreti-
noin in 2001. cDatabase of Teratology Information Services, requests for information.
 2011 The Authors
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one child with preaxial polydactyly. Of the 132 infants (six
twins) who were born before isotretinoin was given, one
child had a cleft lip and palate. Only three women were iden-
tified who had used isotretinoin during pregnancy; all three
infants were normal. These three women did not use oral
contraceptives or IUDs during isotretinoin treatment.
In Denmark11 a questionnaire was circulated to 185 derma-
tologists 20 years after the introduction of isotretinoin; 132
questionnaires were returned with a response rate of 71%.
Post-treatment advice on avoiding pregnancy differed from
1 month in 29% to 2 months in 42%, 3 months in 15% and
more than 3 months in 11%.
A prospective survey was performed in France in 2001, and
published in 2004,12 in 50% of the 182 pharmacies of the
Coˆte d’Or. Of these pharmacies, 37 (41%) collected prescrip-
tions of isotretinoin. Sixty-seven patients filled out a question-
naire of whom 74% lived in an urban environment and 26%
lived in a rural or semi-rural environment. The prescriber of
isotretinoin was a dermatologist in 60 cases (89Æ5%). Iso-
tretinoin was prescribed for acne in 66 cases and in one case
for cutaneous lupus. In 53 (79Æ1%) cases the prescription was
the first prescription, in 12 cases (17Æ9%) it was the second
prescription and in two cases (3%) it was the third prescrip-
tion. Five women did not have a pregnancy test. The terato-
genic risk was known to 48 women (71Æ6%) through friends
before consulting the physician. Seventeen women (25Æ3%)
never received an information leaflet. Of the women who had
read the information before, 87% had the pregnancy test in
accordance with the PPP. In contrast, of the women who read
the information later or who did not receive an information
leaflet, 57% had a pregnancy test in accordance with the PPP
(P = 0Æ007). Thirty-eight women (56Æ7%) were not aware
that contraception should continue after stopping isotretinoin;
however, they continued the contraception for even more
than 1 month (median of 3 months).
The Italian study13 evaluated the system of the isotretinoin
PPP in Italy and was performed by Telefono Rosso (TR), a
member of the European Network of Teratology Information
Services (ENTIS). During the period from July 2002 to Octo-
ber 2005, 52 patients contacted TR, including 19 requests
(36Æ5%) for information pre-conception, 29 pregnancies
(55Æ8%) including four pregnancies concerning paternal
exposure. The 29 pregnancies consisted of pregnancies in
which the patient discontinued isotretinoin 1 month or more
before pregnancy. Data from 35 of the 52 women could be
used for evaluation with the following additional results (not
presented in Table 4): indication was not followed correctly
in 10 women (28Æ6%), claim of not receiving clear and pre-
cise information on teratogenicity in five women (14Æ3%),
and treatment started on 2nd or 3rd day of menstruation in
nine women (25Æ7%). In addition to the study, a case was
reported of a child with complex cardiopathy and bilateral
anotia born to a woman using isotretinoin until the 5th week
of pregnancy (see Table 2).
A prospective observational study was performed in
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2007. A total of 1263 patients were included of whom 56%
were male (n = 709) and 44% were female (n = 554); 296
dermatologists participated of whom 72% were female. The
mean age of the physicians was 48 ± 7 years. A pregnancy
test 5 weeks after stopping isotretinoin was not evaluated.
One month before starting treatment with isotretinoin 548
women used effective contraception. An oral contraceptive
was used by 98% and the remaining 2% used an implantable
progestogen, IUD or were menopausal. In 13% of the women
contraceptives were temporarily interrupted with a maximum
duration of one cycle.
The most recent study was performed in Germany15 in
which pregnancies occurring during isotretinion use recorded
between 1993 through 2008 were evaluated on their preg-
nancy outcome. In total 230 information requests on oral iso-
tretinoin were received during the covered period by the
Teratology Information Service (TIS). In 108 of these 230
cases, isotretinoin was used during the period of 1 month
prior to conception and ⁄or during pregnancy. If information
on contraceptive measures was available (n = 69), 69Æ9% did
not use contraceptive measures and 30Æ4% (n = 21) used con-
traception which failed. All patients did not use two comple-
mentary contraceptive measures as recommended by the
isotretinoin PPP. The 91 known pregnancy outcomes were
compared with controls, comprising prospective enrolled
pregnancies of women who have been exposed to nonterato-
genic agents during the study period. There were 5Æ5% spon-
taneous abortions vs. 10Æ1% in the control group, 75Æ8%
elective terminations vs. 1Æ9%, and 18 live births (19Æ8%)
including a pair of twins vs. 88Æ0%. Three (16Æ9%) of the 18
live born infants had congenital malformations vs. 8Æ5%,
consisting of major birth defects 5Æ6% (n = 1) vs. 3Æ7%
(n = 12).
Case reports
Eight case reports and their outcomes are presented in
Table 3, one of which was a case report presented in a publi-
cation on a study. The case reports originate mostly from
France with single case reports from Italy, Belgium and
Greece.
In two case reports of French origin,16,17 concentrations of
isotretinoin and its metabolites were determined in fetal tissue.
The first case was described in both publications.
Discussion
A systematic literature review was performed in Medline and
Embase on studies and case reports using MeSH terms isotre-
tinoin, pregnancy and Europe. A total of 17 publications were
identified of which 10 were studies, including two surveys
and seven were publications of case reports. The studies evalu-
ated compliance with the isotretinoin PPPs in these countries.
A common conclusion of all the studies and surveys was that
compliance was regarded as insufficient and that the PPP
should be strengthened. The case reports indicate that preg-
nancies occurred despite the fact that a PPP for isotretinoin
was in place.
A limiting factor in the three French studies could be the
fact that pharmacists performed the interviews. Pharmacists
are participants in the control process and the answers might
also concern their compliance with the programme. Therefore,
possible bias cannot be excluded.
Due to the different periods of data collection and the
changes over time in the PPPs, the introduction of generic
drugs, and the regulatory referral of isotretinoin, a comparison
of the results of the studies and surveys and comparison of
the routine risk minimization activities in different countries
is difficult.
This review reveals deficiencies in the implementation of
the isotretinoin PPP. Poor compliance was shown among oth-
ers by failure of contraceptive measures causing 30% of the
pregnancies. Responsibility for this poor compliance seems to
lie with prescribers, patients, pharmacists and also the regula-
tory authorities.
It can be discussed whether Diane-35 or Diannette are
acceptable contraceptives in this situation. These medicinal
products are authorized for the treatment of acne in women
and also have contraceptive action. Prescribing these products
for contraceptive use should be considered carefully, because
of the high risk of thrombosis, which is even higher than in
third-generation oral contraceptives.
The efficacy of the PPP in the prevention of pregnancies is
important as more and more teratogenic drugs become avail-
able for use, for example lenalidomide and thalidomide. How-
ever, these drugs have mostly oncological indications and are
not likely to be prescribed to women of childbearing age.
Isotretinoin on the other hand is prescribed for an aesthetic
problem, which is not life-threatening or causing disability in
the age group of childbearing potential, and has a high risk
for congenital malformations when used just before or during
pregnancy.
The EU PPP was evaluated in 2002–3 during a regulatory
procedure and because of pregnancies reported throughout
Europe. The Pharmacovigilance Working Party (PhVWP) of
the Committee of Human Medicinal Products (CHMP) of the
European Commission is monitoring the current PPP for iso-
tretinoin on a regular basis. The regulatory authority of the
U.K., which is the Reference Member State in Europe for
Roaccutane, reported that up to January 2010, 105 risk-
exposed pregnancies had been spontaneously reported in the
U.K. This was mentioned in a recent publication on the guide-
lines for isotretinoin use in the U.K.23 This publication also
presents results from an audit performed by the British Associ-
ation of Dermatologists (BAD) on isotretinoin use and three
out of the four audit points concerned the PPP.
Recently, another tretinoin has been approved for the Euro-
pean market, namely alitretinoin for use in the treatment of
eczema. This product’s PPP will be closely monitored because
this product will also be prescribed for a relatively young
population including women of childbearing age. Adherence
to a strict programme such as iPledge is a burden for all stake-
 2011 The Authors
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holders and there is no way of completely avoiding human-
related failure.
The isotretinoin PPP has to be evaluated and closely moni-
tored in all countries but also better-designed studies will have
to be performed to gain insight into the full picture before
taking any new measures. This review of studies in Europe
performed so far shows failures in the implementation of this
PPP. Therefore, the isotretinoin PPP must be scrutinized to
identify whether new measures should be taken or whether
the failures in the implementation need to be corrected. New
measures should take into account the definition of the ulti-
mate goal of a PPP and the acceptable burden. In the mean-
time, stakeholders could make a start with adjustments in the
implementation of the PPP by taking responsibility and
enhancing the performance by explicit instructions, monitor-
ing the performance and adjusting, if necessary.
What’s already known about this topic?
• The situation of pregnancies and isotretinoin use in the
U.S.A.
• Occurrence of pregnancies despite an isotretinoin preg-
nancy prevention programme (PPP).
• Compliance with the PPP in the U.S.A.
What does this study add?
• A review of the studies and case reports in Europe.
• An overview of the European situation.
• Identification of compliance issues with the PPP in
Europe.
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